Earnings Insights · RARE · Q3 FY2026
Ultragenyx Q3 2026 Earnings: Cost Reset and Gene-Therapy Launches Put 2027 Profitability in Focus
By AlgovestIQ ResearchPublished
Read Ultragenyx Pharmaceutical’s results announcement (Form 8-K, filed Nov 3, 2026)
Key earnings findings
Ultragenyx Pharmaceutical (RARE) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Ultragenyx Pharmaceutical reported Q3 FY2026 revenue of $173.0M against the $182.5M analyst estimate, 5.2% below it, and EPS of -$1.16 against the -$1.10 analyst estimate, 5.5% below it.
- Ultragenyx reaffirmed full-year 2026 total revenue guidance of $730M to $760M.
- RARE closed at $17.16 on Nov 4, 2026, up 3.2% from $16.63 on Nov 3, 2026, the last close before the results were released.
Sources: Ultragenyx Pharmaceutical results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Ultragenyx Pharmaceutical beat earnings expectations?
- Revenue surprise across the last 8 reported quarters has ranged from -19.9% to 16.9%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Ultragenyx reported third-quarter revenue of $173M, up from $160M a year earlier, while its GAAP net loss narrowed to $118M, or $1.16 per share, from $180M, or $1.81 per share. The quarter was defined less by the modest top-line increase than by a strategic reset: two gene therapies received FDA approval, but disappointing late-stage results in Angelman syndrome and insufficient response data in Wilson disease prompted program terminations, a 20% workforce reduction, and materially lower planned R&D spending.
Management reaffirmed 2026 revenue guidance and its expectation of full-year GAAP profitability in 2027. The investment case now depends on whether the established rare-disease portfolio and the launches of GENGLYCOS and FAYUVI can support that profitability target while Ultragenyx operates with a narrower development pipeline.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Total revenue | $173M | Up 8% year over year |
| CRYSVITA revenue | $109M | Down 3% |
| DOJOLVI revenue | $30M | Up 25% |
| EVKEEZA revenue | $24M | Up 41% |
| MEPSEVII revenue | $10M | Up 43% |
| R&D expense | $154M | Down 29% |
| SG&A expense | $97M | Up 11% |
| Total operating expenses | $283M | Down 15% |
| Loss from operations | $(110M) | Improved from $(171M) |
| GAAP net loss | $(118M) | Improved from $(180M) |
| GAAP loss per share | $(1.16) | Improved from $(1.81) |
| Cash, cash equivalents and marketable securities | $401M | Down from $737M at year-end 2025 |
| Net cash used in operations | $43M | — |
The Bigger Story
Ultragenyx is shifting from a broad late-stage development organization toward a commercial-stage rare-disease company with a smaller R&D footprint. The company plans to reduce headcount by about 20% to roughly 1,000 employees, wind down GTX-102 for Angelman syndrome, terminate UX701 for Wilson disease, reduce its real-estate footprint, and lower corporate spending.
The reset follows a difficult clinical period. GTX-102 did not demonstrate efficacy in its Phase 3 Angelman study, which management attributed to substantial variability in the control group across multiple endpoints. UX701 showed clinical activity in some Wilson disease patients but did not meet Ultragenyx’s threshold for advancing into Phase 3: a majority of patients achieving biochemical response and discontinuing standard-of-care therapy.
Those setbacks reduce the company’s late-stage pipeline breadth. However, FDA approvals for GENGLYCOS in glycogen storage disease type Ia and FAYUVI in Sanfilippo syndrome type A provide two new commercial assets, alongside a portfolio led by CRYSVITA, DOJOLVI and EVKEEZA.
The financial consequence is clear. Management now expects 2027 R&D spending of less than $350M, more than 50% below 2025 levels, while continuing to target full-year GAAP profitability and positive operating cash flow in 2027.
Revenue and Operating Performance
Revenue increased 8% to $173M in the third quarter. Growth was driven by DOJOLVI, EVKEEZA and MEPSEVII, which more than offset a modest decline in CRYSVITA revenue.
CRYSVITA generated $109M, compared with $112M a year earlier. Product sales in Latin America and Türkiye fell to $41M from $47M, while U.S. and Canada royalty revenue increased to $61M from $57M. European royalty revenue declined to $7M from $8M. Management characterized the quarterly result as consistent with expected ordering patterns and said underlying demand remains steady.
Commercial patient additions in Latin America remained positive, with about 60 new patients starting CRYSVITA therapy during the quarter and more than 1,050 patients on commercial treatment in the region. Management noted that distributor and ordering patterns can create quarter-to-quarter variability.
DOJOLVI revenue rose 25% to $30M. Management said nearly 700 patients in North America are on reimbursed therapy, while approximately 315 patients in Europe, the Middle East and Africa are receiving treatment through named-patient or early-access programs. The product recently received conditional marketing authorization in the U.K. for the full long-chain fatty acid oxidation disorder indication.
EVKEEZA was the largest growth contributor, with revenue increasing 41% to $24M. The company attributed the increase to new-country launches and early-access activity. More than 500 patients across over 20 countries are now receiving EVKEEZA in Ultragenyx’s commercial territories outside the U.S.
MEPSEVII revenue increased to $10M from $7M.
The newly approved gene therapies did not contribute to the company’s 2026 revenue guidance, and management has not yet provided product-specific revenue expectations. Instead, early launch indicators will include qualified treatment center activation, enrollment forms, payer coverage, and eventually patients treated and revenue.
Profitability and Margins
Ultragenyx’s GAAP net loss narrowed by $62M year over year to $118M. The improvement reflected revenue growth and a $62M reduction in R&D expense, which fell to $154M as several late-stage programs concluded or were reduced.
SG&A expense rose to $97M from $87M, partly reflecting the costs of supporting an expanding commercial portfolio and preparing for gene-therapy launches. Cost of sales increased to $32M from $28M.
The reported operating loss improved to $110M from $171M. Below the operating line, non-cash interest expense on liabilities for sales of future royalties increased to $20M from $14M. A $9M income-tax benefit also helped narrow the net loss.
Third-quarter operating expenses included $34M of non-cash stock-based compensation. The company expects approximately $25M of severance and other non-recurring restructuring charges in the fourth quarter, following $30M of restructuring expense recorded through the first nine months of 2026.
The key point for investors is that the path to profitability relies on structural expense reductions rather than a near-term step-change in reported revenue. Management expects the reduced cost base, growth in the existing portfolio, and contributions from the two gene-therapy launches to produce GAAP net income profitability in 2027.
Demand, Customers and Pricing
Management reported early demand for both GENGLYCOS and FAYUVI, with enrollment forms received and some patients scheduled for reimbursed infusions. As of the end of October, Ultragenyx had activated 35 qualified treatment centers and remained on track to exceed 40 by year-end.
FAYUVI may see a faster initial launch cadence because Sanfilippo syndrome Type A is a progressive pediatric neurological disease and management described demand as urgent from families and physicians. Early payer policies have been consistent with the product label, according to management, though coverage decisions are initially being made patient by patient.
GENGLYCOS is likely to have a more measured adoption curve. Patients with glycogen storage disease type Ia already have disease-management options, but GENGLYCOS could reduce dependence on frequent cornstarch dosing and potentially reduce the risk of hypoglycemic events.
Both launches face typical gene-therapy adoption constraints: treatment-center readiness, individual reimbursement decisions, patient eligibility, and the operational process required before infusion. GENGLYCOS also carries an accelerated approval, with a confirmatory post-marketing study required to verify clinical benefit.
What is Ultragenyx’s 2026 and 2027 outlook?
Ultragenyx reaffirmed full-year 2026 total revenue guidance of $730M to $760M. That outlook excludes revenue from GENGLYCOS and FAYUVI launches.
The company also reaffirmed 2026 guidance for:
- CRYSVITA revenue of $500M to $520M
- DOJOLVI revenue of $100M to $110M
- Combined R&D and SG&A expense flat to down low single digits versus 2025
For 2027, management expects:
- R&D expense of less than $350M
- SG&A expense of less than $375M
- Full-year GAAP net income profitability
- Positive cash flow from operating activities
Management said most 2027 R&D expense will support commercial products, including post-marketing obligations, regulatory activity and disease-monitoring programs. Spending will also support the Phase 3 DTX301 program in ornithine transcarbamylase deficiency, regulatory discussions around UX143 in osteogenesis imperfecta, and selective early-stage work.
DTX301 remains the company’s principal late-stage pipeline catalyst. Additional Phase 3 data evaluating reduction in ammonia-scavenger use and dietary management are expected in the first half of 2027. Management described the existing blinded data as showing improved ammonia control and global impression scores, but the next dataset will be important for determining the regulatory and commercial profile.
The path forward for UX143 remains unresolved. Management believes the Phase 3 program showed activity in bone mineral density and in subsets of patients with higher fracture rates, but it is still discussing with regulators whether the existing data can support a filing or whether another study will be needed.
Balance Sheet, Cash Flow and Capital
Ultragenyx ended September with $401M in cash, cash equivalents and marketable securities, down from $737M at the end of 2025. Net cash used in operations was $43M in the third quarter.
The balance sheet is set to improve materially through the sale of two priority review vouchers received upon the approvals of GENGLYCOS and FAYUVI. The two agreements have a combined sale price of $413M, with estimated net proceeds of approximately $350M after payments to licensors and fees.
The GENGLYCOS voucher sale, valued at $210M, closed in October. The FAYUVI voucher sale, valued at $203M, was expected to close later in the month. Management said the proceeds will be recorded as other income in 2026 and are not included in its underlying 2027 profitability assumptions.
Management also said it expects the PRV proceeds and existing cash to fund the company through profitability without additional fundraising. That statement reduces near-term financing risk, although execution against the operating plan remains essential as cash balances have fallen substantially over the past nine months.
What Investors Should Watch
1. Gene-therapy launch conversion
The key early measures for GENGLYCOS and FAYUVI will be treatment-center activation, payer coverage, patient enrollment and completed infusions. Strong demand is encouraging, but gene-therapy revenue depends on converting interest into reimbursed treatments.
2. Delivery of the 2027 cost structure
Ultragenyx’s profitability target depends heavily on reducing R&D below $350M and SG&A below $375M. Investors should monitor restructuring execution, fourth-quarter charges, workforce-reduction completion, and whether commercial support costs remain within plan.
3. CRYSVITA’s underlying growth
CRYSVITA remains Ultragenyx’s largest revenue source despite its 3% year-over-year decline in the quarter. Sustained patient growth, particularly in Latin America, and stability in royalty revenue are important to supporting the company’s base business.
4. DTX301 Phase 3 data
Data expected in the first half of 2027 will clarify whether DTX301 can become the company’s next meaningful pipeline-derived revenue opportunity. The study’s endpoint on reducing ammonia-scavenger use and dietary management is particularly important following the favorable ammonia-control results already discussed by management.
5. UX143 regulatory path
Ultragenyx sees evidence of activity for setrusumab in osteogenesis imperfecta, particularly in patients with more frequent fractures. The unresolved question is whether regulators will accept existing evidence or require an additional trial, which would affect timing, cost and the remaining pipeline’s value.
AlgovestIQ Takeaway
Ultragenyx produced a financially improved quarter, but the strategic significance lies in the company’s sharper focus rather than its 8% revenue growth. R&D spending fell materially, the net loss narrowed, and the PRV sales provide approximately $350M of expected net proceeds that should ease liquidity concerns.
The company has also improved its commercial opportunity set. GENGLYCOS and FAYUVI add two approved gene therapies, and management has reported favorable early physician and patient engagement. FAYUVI in particular may have meaningful initial demand because of the severity and progression of Sanfilippo syndrome Type A.
Still, the cost reductions were prompted by real pipeline setbacks. The termination of GTX-102 and UX701 narrows future optionality, while UX143’s regulatory path remains uncertain. Ultragenyx is increasingly dependent on execution in its marketed portfolio, successful conversion of gene-therapy demand into reimbursed treatment, and a positive outcome for DTX301.
The central investment question is whether the company can translate its larger commercial portfolio into durable profitability without sacrificing too much future pipeline value. Evidence that the thesis is working would include steady CRYSVITA and DOJOLVI growth, early gene-therapy treatment conversion, declining cash burn, and disciplined delivery of 2027 expense targets. Delays in reimbursement, slower launch uptake, or another setback in the remaining late-stage pipeline would weaken the path to sustainable profitability.
How did RARE stock react?
RARE closed at $17.16 on Nov 4, 2026, up 3.2% from $16.63 on Nov 3, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Nov 3, 2026 (before release) | $16.63 | — |
| Nov 4, 2026 | $17.16 | +3.2% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- BNTXBioNTech Q3 2026 Earnings: BMS Collaboration Revenue Lifts Quarter as Oncology Pipeline Takes Center StageNov 3, 2026
- RXRXRecursion Q3 2026 Earnings: Clinical Progress and Financing Extend Runway Into 2029Nov 3, 2026
- VRTXVertex Q3 2026 Earnings: Revenue Growth Holds as Crinetics Acquisition Reshapes the Cost BaseNov 2, 2026
- SRPTSarepta Therapeutics Q3 2026 Earnings: PMO Strength Offsets a Stabilized but Smaller ELEVIDYS BusinessNov 5, 2026
- MRNAModerna Q3 2026 Earnings: Raised Revenue Outlook as COVID Sales and Cost Cuts Restore ProfitabilityNov 6, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Ultragenyx Pharmaceutical Q3 FY2026 earnings call transcript, as of Nov 3, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Ultragenyx Pharmaceutical Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 3, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 3, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.